Search Result

Results for "

chronic cough

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Antibiotic (1) Apoptosis (1) Bacterial (1) Cannabinoid Receptor (3) Cytochrome P450 (1) Dopamine Receptor (1) Endogenous Metabolite (1) Histamine Receptor (2) Influenza Virus (1) MicroRNA (1) nAChR (3) Neurokinin Receptor (2) P2X Receptor (12) p38 MAPK (1) Phosphodiesterase (PDE) (1) Reference Standards (3) Sodium Channel (2) Topoisomerase (1) TRP Channel (4)
By Research Areas:	Cancer (1) Infection (1) Inflammation/Immunology (24) Metabolic Disease (1) Neurological Disease (14)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-101588

Gefapixant 2 Publications Verification MK-7264; AF-219	P2X Receptor	Inflammation/Immunology
Gefapixant is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC₅₀ values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis .

HY-109170

Eliapixant BAY 1817080	P2X Receptor	Inflammation/Immunology
Eliapixant (BAY 1817080) is a potent and selective antagonist of P2X3 receptor, with an IC₅₀ of 8 nM. Eliapixant can be used for the research of refractory chronic cough .

HY-136026

Camlipixant BLU-5937	P2X Receptor	Inflammation/Immunology
Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC₅₀ of 25 nM against hP2X3 homotrimeric. Camlipixant shows potent anti-tussive effect and no taste alteration. Camlipixant can be used for the research of unexplained, refractory chronic cough .

HY-101588A

Gefapixant citrate 2 Publications Verification MK-7264 citrate; AF-219 citrate	P2X Receptor	Inflammation/Immunology
Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC₅₀ values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis .

HY-122575

Aurintricarboxylic acid 3 Publications Verification	P2X Receptor Influenza Virus Topoisomerase MicroRNA Apoptosis	Infection Neurological Disease Inflammation/Immunology
Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC₅₀s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively . Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase . Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis . Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway . Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC₅₀ of 0.6 μM . Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC₅₀ of 0.47 µM .

HY-A0191

Dexbrompheniramine (+)-Brompheniramine; (S)-Brompheniramine	Endogenous Metabolite Histamine Receptor TRP Channel	Neurological Disease Metabolic Disease Inflammation/Immunology
Dexbrompheniramine ((+)-Brompheniramine; (S)-Brompheniramine) is a dual inhibitor of histamine H1 receptor and TRPV1 receptor that can cross the blood-brain barrier. Dexbrompheniramine exerts its effects by functionally blocking H1 receptor activity and dose-dependently inhibiting TRPV1-mediated calcium responses, including Capsaicin (HY-10448)-induced responses. The combination of Dexbrompheniramine with Cimetidine (HY-14289) eliminates histamine-induced and sham-feeding-induced drinking behavior, whereas Dexbrompheniramine alone does not induce thirst or alter sham-feeding behavior in rats. Dexbrompheniramine can be used in the research of chronic cough and related pathological mechanisms .

HY-148802

Taplucainium chloride	Sodium Channel	Inflammation/Immunology
Taplucainium chloride is a sodium channel blocker. Taplucainium chloride selectively inhibits nociceptors in an activated or inflammatory state. Taplucainium chloride may be used in research on chronic cough .

HY-101765

GW 833972A	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW 833972A is a selective CB₂ receptor agonist with pEC₅₀ of the human CB₂ receptor for GW 833972A of 7.3, and its selectivity for the CB₂ receptor is approximately 1000 times higher than that for the CB₁ receptor. GW 833972A inhibits induced neuronal depolarization and suppresses coughing caused by citric acid in guinea pig models. GW 833972A can be used for the study of chronic cough .

HY-18060

Bradanicline TC-5619	nAChR	Neurological Disease
Bradanicline (TC-5619) is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .

HY-156684

Nedizantrep GDC-6599	TRP Channel	Neurological Disease
GDC-6599 is an orally active TRPA1 inhibitor, with IC₅₀ values of 5.3 nM in humans, 6.6 nM in rats, 9.3 nM in dogs, 7.2 nM in monkeys, and 15 nM in guinea pigs. GDC-6599 can be used in the research of neuropathic pain and respiratory diseases such as asthma and chronic cough .

HY-143481

Nav1.8-IN-2	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-2 (compound 35A) is a Nav1.8 voltage-gated sodium ion inhibitor with an IC₅₀ of 0.4 nM (HEK 293 cells). Nav1.8-IN-2 inhibits the activity of Nav1.8 voltage-gated sodium ion channels, mediates sodium ion influx in excitable cells, and is associated with the initiation and conduction of action potentials. Nav1.8-IN-2 can be used for research related to pain, cough, itching, etc .

HY-122347A

Orvepitant maleate GW823296 maleate	Neurokinin Receptor	Neurological Disease Inflammation/Immunology
Orvepitant maleate (GW823296 maleate) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pK_i of 10.2 for human neurokinin-1 receptor. Orvepitant maleate can across the blood-brain barrier. Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatment .

HY-135976

P2X3 antagonist 34	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC₅₀s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect .

HY-109173

Filapixant BAY 1902607	P2X Receptor Cytochrome P450	Inflammation/Immunology
Filapixant (BAY 1902607) is an orally active and selective P2X3 receptor antagonist. Filapixant is applicable to the research of refractory chronic cough .

HY-178450

HW091077	P2X Receptor	Neurological Disease
HW091077 is a highly selective P2X3 receptor antagonist with an IC₅₀ of 17 nM. HW091077 blocks ATP-induced calcium influx and cell depolarization to inhibit cough reflex pathways. HW091077 is promising for research of chronic cough .

HY-B0372

Bromhexine 3 Publications Verification	Antibiotic Bacterial	Inflammation/Immunology
Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases .

HY-A0191A

Dexbrompheniramine maleate (+)-Brompheniramine maleate; (S)-Brompheniramine maleate	TRP Channel Histamine Receptor	Inflammation/Immunology
Dexbrompheniramine ((+)-Brompheniramine; (S)-Brompheniramine) maleate is a dual inhibitor of histamine H1 receptor and TRPV1 receptor that can cross the blood-brain barrier. Dexbrompheniramine maleate exerts its effects by functionally blocking H1 receptor activity and dose-dependently inhibiting TRPV1-mediated calcium responses, including Capsaicin (HY-10448)-induced responses. The combination of Dexbrompheniramine maleate with Cimetidine (HY-14289) eliminates histamine-induced and sham-feeding-induced drinking behavior, whereas Dexbrompheniramine maleate alone does not induce thirst or alter sham-feeding behavior in rats. Dexbrompheniramine maleate can be used in the research of chronic cough and related pathological mechanisms .

HY-101588R

Gefapixant (Standard) MK-7264 (Standard); AF-219 (Standard)	Reference Standards P2X Receptor	Inflammation/Immunology
Gefapixant (Standard) is the analytical standard of Gefapixant. This product is intended for research and analytical applications. Gefapixant is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC₅₀ values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis .

HY-18060A

Bradanicline hydrochloride TC-5619 hydrochloride	nAChR	Neurological Disease
Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline hydrochloride exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline hydrochloride possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline hydrochloride requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline hydrochloride is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .

HY-122347

Orvepitant GW823296	Neurokinin Receptor	Neurological Disease Cancer
Orvepitant (GW823296) is potent, selective, orally active and well-tolerated neurokinin-1 receptor (NK-1) antagonist with a pK_i of 10.2 for human neurokinin-1 receptor. Orvepitant can across the blood-brain barrier. Orvepitant has the potential for depressive disorder and chronic refractory cough (CRC) treatment .

HY-124270

Sibenadet hydrochloride AR-C68397AA	Dopamine Receptor Adrenergic Receptor	Inflammation/Immunology
Sibenadet hydrochloride (AR-C68397AA) is a dual D2 dopamine receptor, beta2-adrenoceptor agonist with bronchodilator activity. Investigation in animal models of key chronic obstructive pulmonary disease (COPD) symptoms has demonstrated that Sibenadet hydrochloride effectively inhibits sensory nerve activity, thereby reducing reflex cough, mucus production and tachypnoea.

HY-172135

PDE4-IN-26	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .

HY-101588AR

Gefapixant citrate (Standard) MK-7264 citrate (Standard); AF-219 citrate (Standard)	P2X Receptor Reference Standards	Inflammation/Immunology
Gefapixant (citrate) (Standard) is the analytical standard of Gefapixant (citrate) (HY-101588A). This product is intended for research and analytical applications. Gefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis .

HY-18060B

Bradanicline tosylate TC-5619 tosylate	nAChR	Inflammation/Immunology
Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline tosylate exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline tosylate possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline tosylate requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline tosylate is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .

HY-N18663

Lavandula officinalis extract	Others	Inflammation/Immunology
Lavandula officinalis extract is widely used in research on complex respiratory diseases, such as chronic cough and asthma.

HY-186112

PSFL2915	P2X Receptor	Inflammation/Immunology
PSFL2915 is a selective, orally active P2X receptor inhibitor with oral effectiveness, with an IC₅₀ of 0.319 μM for human P2X3, 0.261 μM for rat P2X2/3, and 13.3 μM for human P2X2. PSFL2915 exhibits ~42-fold selectivity over human P2X2. PSFL2915 can be used for the research of chronic cough .

HY-180365

GW 833972A free base	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW 833972A free base is a selective CB₂ receptor agonist with pEC₅₀ of the human CB₂ receptor for GW 833972A free base of 7.3, and its selectivity for the CB₂ receptor is approximately 1000 times higher than that for the CB₁ receptor. GW 833972A free base inhibits induced neuronal depolarization and suppresses coughing caused by citric acid in guinea pig models. GW 833972A free base can be used for the study of chronic cough .

HY-101765R

GW 833972A (Standard)	Reference Standards Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW 833972A (Standard) is the analytical standard of GW 833972A (HY-101765). This product is intended for research and analytical applications. GW 833972A is a selective CB₂ receptor agonist with pEC₅₀ of the human CB₂ receptor for GW 833972A of 7.3, and its selectivity for the CB₂ receptor is approximately 1000 times higher than that for the CB₁ receptor. GW 833972A inhibits induced neuronal depolarization and suppresses coughing caused by citric acid in guinea pig models. GW 833972A can be used for the study of chronic cough .

HY-183056

P2X3 antagonist 40	P2X Receptor	Others Neurological Disease Inflammation/Immunology
P2X3 antagonist 40 is a P2X3 antagonist with a human P2X3 receptor pIC₅₀ < 4.52. P2X3 antagonist 40 can be used for research on ATP-mediated proinflammatory fingerprint, including overactive bladder, pain, and chronic cough .

HY-185006

TRPV4 antagonist 5	TRP Channel	Others
TRPV4 antagonist 5 (Example 21) is a TRPV4 antagonist .

Cat. No.	상품명

HY-L223

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library	862 compounds
Antitussive and antiasthmatic method is a type of treatment strategy in traditional Chinese medicine, mainly used to alleviate symptoms such as coughing and asthma. These symptoms may be caused by various factors, such as: Bronchial asthma, chronic obstructive pulmonary disease, asthmatic bronchitis, cough-induced asthma, and others. Based on existing research in traditional Chinese medicine, many types of Chinese medicinal herbs showed antitussive and antiasthmatic effects. For example: Ardisiae Japonicae Herba, Ginkgo Semen, Amygdalus Communis Vas, Farfarae Flos, Viticis Cannabifoliae Fructus, Eriobotryae Folium etc. Therefore, the active ingredients derived from these traditional Chinese medicine have high medicinal value and have the potential to be developed into drugs for related diseases. MCE can provide 862 active ingredients that can be obtained from traditional Chinese medicine with antitussive and antiasthmatic functions, which can be applied to drug development and research on disease mechanisms.

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

862 compounds

Antitussive and antiasthmatic method is a type of treatment strategy in traditional Chinese medicine, mainly used to alleviate symptoms such as coughing and asthma. These symptoms may be caused by various factors, such as: Bronchial asthma, chronic obstructive pulmonary disease, asthmatic bronchitis, cough-induced asthma, and others. Based on existing research in traditional Chinese medicine, many types of Chinese medicinal herbs showed antitussive and antiasthmatic effects. For example: Ardisiae Japonicae Herba, Ginkgo Semen, Amygdalus Communis Vas, Farfarae Flos, Viticis Cannabifoliae Fructus, Eriobotryae Folium etc. Therefore, the active ingredients derived from these traditional Chinese medicine have high medicinal value and have the potential to be developed into drugs for related diseases.

MCE can provide 862 active ingredients that can be obtained from traditional Chinese medicine with antitussive and antiasthmatic functions, which can be applied to drug development and research on disease mechanisms.

HY-L238

Mongolian Medicine Compound Library	2,383 compounds
Mongolian medicine refers to drugs used for disease prevention and treatment under the guidance of Mongolian medical theory. Originating from the vast grasslands and desert regions of northern China, Mongolian medicine developed under specific natural conditions and a nomadic lifestyle, forming a unique theoretical system and treatment methods. It emphasizes the balance between the human body and the natural environment and has demonstrated distinct efficacy in treating digestive system diseases, rheumatism, skin diseases, and various chronic conditions. For example, Mongolian medicine often uses Chinese red date for palpitations and angina pectoris, sea buckthorn to relieve coughs, reduce phlegm, promote blood circulation, and remove blood stasis, and scabious to clear lung heat and treat liver heat diseases. The application of these characteristic Mongolian medicines embodies the profound wisdom of Mongolian medical practice. With the advancement of modern technology, research on Mongolian medicine continues to deepen. Systematic studies on the chemical composition and pharmacological effects of Mongolian medicines can provide new ideas and methods for modern drug development. MCE has collected 2,383 characteristic natural products derived from Mongolian medicines, with 400+ plant sources of Mongolian medicine.

Mongolian Medicine Compound Library

2,383 compounds

Mongolian medicine refers to drugs used for disease prevention and treatment under the guidance of Mongolian medical theory. Originating from the vast grasslands and desert regions of northern China, Mongolian medicine developed under specific natural conditions and a nomadic lifestyle, forming a unique theoretical system and treatment methods. It emphasizes the balance between the human body and the natural environment and has demonstrated distinct efficacy in treating digestive system diseases, rheumatism, skin diseases, and various chronic conditions. For example, Mongolian medicine often uses Chinese red date for palpitations and angina pectoris, sea buckthorn to relieve coughs, reduce phlegm, promote blood circulation, and remove blood stasis, and scabious to clear lung heat and treat liver heat diseases. The application of these characteristic Mongolian medicines embodies the profound wisdom of Mongolian medical practice.

With the advancement of modern technology, research on Mongolian medicine continues to deepen. Systematic studies on the chemical composition and pharmacological effects of Mongolian medicines can provide new ideas and methods for modern drug development.

MCE has collected 2,383 characteristic natural products derived from Mongolian medicines, with 400+ plant sources of Mongolian medicine.

Dexbrompheniramine (+)-Brompheniramine; (S)-Brompheniramine	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Histamine Receptor TRP Channel
Dexbrompheniramine ((+)-Brompheniramine; (S)-Brompheniramine) is a dual inhibitor of histamine H1 receptor and TRPV1 receptor that can cross the blood-brain barrier. Dexbrompheniramine exerts its effects by functionally blocking H1 receptor activity and dose-dependently inhibiting TRPV1-mediated calcium responses, including Capsaicin (HY-10448)-induced responses. The combination of Dexbrompheniramine with Cimetidine (HY-14289) eliminates histamine-induced and sham-feeding-induced drinking behavior, whereas Dexbrompheniramine alone does not induce thirst or alter sham-feeding behavior in rats. Dexbrompheniramine can be used in the research of chronic cough and related pathological mechanisms .

Lavandula officinalis extract	Structural Classification Extract	Others
Lavandula officinalis extract is widely used in research on complex respiratory diseases, such as chronic cough and asthma.

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고